Review Article
Genomics in Atrial Fibrillation: A Brief Review
Thomas E. Watts1, Abhishek J. Deshmukh2*, Sadip Pant1, Juan Viles-Gonzalez3 and Hakan Paydak2
1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
2Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
3Division of Cardiology, Department of Internal Medicine, University of Miami, Miami, Florida, USA
- Corresponding Author:
- Abhishek J Deshmukh
Division of Cardiology
Department of Internal Medicine
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
Tel: 1-414-581-2153
Fax: 1-414-581-2153
E-mail: [email protected]
Received date: February 16, 2014; Accepted date: May 26, 2014; Published date: June 20, 2014
Citation: Watts TE, Deshmukh AJ, Pant S, Gonzalez JV and Paydak H (2014) Genomics in Atrial Fibrillation: A Brief Review. J Mol Genet Med 8:114. doi: 10.4172/1747-0862.1000114
Copyright: © 2014 Deshmukh AJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Abstract
Genomics in Atrial Fibrillation Atrial fibrillation (AF) carries a significant burden in the form of morbidity, mortality, and cost to the healthcare system. According to the Center for Disease Control, AF is the most common cardiac arrhythmia in the United States with an incidence of 2.26 million people in 2010 that is expected to increase to 12 million people by 2050 [1]. The mortality rate from AF as a primary or secondary cause of death is increasing, as is the cost burden to the healthcare system [1]. It is estimated that in the year 2005, the cost to the U.S. healthcare system for treating AF was $6.65 billion
